Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: ADEL 7 who wrote (192)	11/11/1998 8:28:00 PM
From: yosi s	Respond to of 1386

Adel a this stage phase 2 study is best publish in its appropriate section. And as it has to do with TBI Neurosurgery is the most appropriate. that is my opinion. Though I agree the NEJM be greater coverage. I expect the stroke study to be there. or in Neurology. Please note: the Lancet has a publication for the general public. as well as for physician. I agree with your assesment regarding Lancet's medical publication for physicians.

To: ADEL 7 who wrote (192)	11/12/1998 8:11:00 PM
From: Gabe Fernandez	Read Replies (2) \| Respond to of 1386

Adel we both have the same goal of letting all medical personnel know about Pharmos HU-211 and the widest read journal amongst internist and gen practicioners is the New England Journal of Medicine. Can you imagine the Intensive Care grapevine talking about this new drug (a derivative of Marihuana) that is controlling intracranial pressure and improving outcomes with the addition of saving lives. Just the hospital rumor network will alert newspapers and other news media. Thirty five years ago the darling of head trauma management was HYPOTHERMIA,later Barbiturate Coma,it spread through University hospitals all over the country. IF HU-211 works everyone in medicine including nurses,emergency room attendants and EMT personnel will be aware of the same,we just need a study that will be respected by all